Glioblastoma multiforme classification

Glioblastoma multiforme Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glioblastoma multiforme from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glioblastoma multiforme classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glioblastoma multiforme classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glioblastoma multiforme classification
CDC on Glioblastoma multiforme classification
Glioblastoma multiforme classification in the news
Blogs on Glioblastoma multiforme classification
Directions to Hospitals Treating Glioblastoma multiforme
Risk calculators and risk factors for Glioblastoma multiforme classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

Glioblastoma multiforme may be classified into several subtypes based on the origin (primary and secondary) and molecular alterations (classic, proneural, mesenchymal, and neural).The heterogeneity of GBM profiles leads to different treatment efficacy among patients. The therapy must be personalized to target each patient’s alterations in the molecular level.

Classification

Based on the origin

Glioblastoma multiforme may be classified according to the origin into two subtypes: Primary and secondary.

Subtype of Glioblastoma multiforme	Characteristic features
Primary glioblastoma multiforme	De novo origin More aggressive Occurs in older patients
Secondary glioblastoma multiforme	Arises from pre-existing lower grade gliomas Less aggressive Occurs in younger patients

• Primary GBM is the most common form (about 95%) and arises typically de novo, within 3–6 months, in older patients.
• Secondary GBM arises from prior low-grade astrocytomas (over 10–15 years) in younger patients.
• Primary and secondary forms show some molecular differences.
• The end result of both sub type is same since the same pathways are affected and respond similarly to current standard treatment.
• Primary GBM often has amplified and mutated epidermal-growth factor receptor (EGFR) which encodes altered EGF receptor.
• Secondary GBM has increased signaling through PDGF-A receptor.
• Both types of mutations lead to increased tyrosine kinase receptor (TKR) activity and consequently to activation of RAS and PI3K pathways.
• Primary and secondary GBM may be indistinguishable histologically but apparently differ in genetic and epigenetic profiles.

Based on the molecular alterations

• the Cancer Genome Atlas (TCGA) divided GBM according to the molecular alterations into four subtypes:

1. Classic
2. Proneural
3. Mesenchymal
4. Neural

• Classical GBM is defined by aberrant EGFR amplification with astrocytic cell expression pattern and loss of chromosome 10.
• The mesenchymal subtype is defined by NF1 and PTEN mutations, a mesenchymal expression profile and less EGFR amplification than in other GBM types.
• The proneural subtype is characterized by PDGFRA focal amplification, TP53 and IDH1 mutations with an oligodenrocytic cell expression profile and younger presentation age.
• The neural subtype is characterized by normal brain tissue gene expression wuth astrocytic and oligodendrocytic cell markers.
• Most GBM tumors with IDH1 mutations have the proneural gene expression pattern but only 30% of preneural GBM has the IDH1 mutation.
• IDH1 mutation is a reliable and definitive molecular diagnostic criterion of secondary GBM compared to clinical criteria.
• The heterogeneity of GBM profiles leads to different treatment efficacy among patients.
• The therapy must be personalized to target each patient’s alterations in the molecular level.

References

Template:WikiDoc Sources